NEBIVOLOL HYDROCHLORIDE

Post-LOE

nebivolol hydrochloride

Teva

ANDAORALTABLET

Approved

Mar 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NEBIVOLOL HYDROCHLORIDE (nebivolol hydrochloride) by Teva is established. Approved for hypertension, to lower blood pressure, to lower blood pressure [see clinical studies ()] and 1 more indications. First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

established. Possible factors that may be involved include: (1) decreased heart rate, (2) decreased myocardial contractility, (3) diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, (4) suppression of renin activity and (5) vasodilation and decreased peripheral…

Indications (2)

hypertension to lower blood pressure

Worked on NEBIVOLOL HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.